PLUS THERAPEUTICS, Inc. Series S Warrant
PSTVZ
PSTVZ was delisted on the 26th of May, 2020.
7 hedge funds and large institutions have $3.56M invested in PLUS THERAPEUTICS, Inc. Series S Warrant in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$12.6K |
| 2 |
JG
Jefferies Group
New York
|
+$10.7K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$3.14K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$2.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.75K |
Top Sellers
PSTVZ Hedge Fund Activity: Q3 2019 in Review
7 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in PLUS THERAPEUTICS, Inc. Series S Warrant (PSTVZ) for Q3 2019, worth a combined $3.56M.
Buyers outnumbered sellers: 7 funds opened new PSTVZ positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $12.6K.
- 7 institutional investors held PLUS THERAPEUTICS, Inc. Series S Warrant (PSTVZ) as of Q3 2019, up from 0 in Q2 2019.
- Funds reported $3.56M of PLUS THERAPEUTICS, Inc. Series S Warrant stock for Q3 2019.
- 7 funds opened new PLUS THERAPEUTICS, Inc. Series S Warrant positions in Q3 2019 and 0 closed out, a net change of +7 holders.
- The largest PLUS THERAPEUTICS, Inc. Series S Warrant buyer in Q3 2019 was Anson Funds Management, an estimated $12.6K added.
Based on aggregated 13F filings for Q3 2019.